Profitability
This table compares Graybug Vision and Eliem Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Graybug Vision | N/A | -77.61% | -71.34% |
| Eliem Therapeutics | N/A | -47.03% | -45.97% |
Volatility & Risk
Graybug Vision has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500.
Insider and Institutional Ownership
49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 7.9% of Graybug Vision shares are held by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Graybug Vision | $426.96 million | 0.00 | -$35.60 million | ($24.23) | -0.03 |
| Eliem Therapeutics | N/A | N/A | -$35.12 million | ($0.53) | -20.68 |
Eliem Therapeutics has lower revenue, but higher earnings than Graybug Vision. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.
Summary
Eliem Therapeutics beats Graybug Vision on 5 of the 9 factors compared between the two stocks.
About Graybug Vision
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
About Eliem Therapeutics
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
